Basket | Login | Register


WP 1: Development and validation of translatable congitive impairment models (Clinical studies)

Work Packages

Pharmacog Logo

Main Objectives:

  • To define and harmonize parallel clinical challenge models of transient cognitive impairment (Sleep Deprivation, Transcranial Magnetic Stimulation, Hypoxia) to support early proof of efficacy studies
  • To assess in 3 challenges: the intensity of the induced cognitive deficit, the time course of the induced cognitive deficit, the acceptability of the challenge used, the sensitivity to change of the outcomes under AD treatment administration
  • To deliver validated protocols for healthy volunteer models with increased predictive capacity to be used in early clinical studies with new experimental treatments of AD.
  • To back-translate data generated to parallel pre-clinical studies (WP2) to identify those challenge paradigms with translational capacity to improve the predictive capacity of pre-clinical models

WP Leads:

Academic Lead: Dr David Bartès-Faz (IDIBAPS, Spain) and Dr Joëlle Micallef (University of Marseille)

WP Partners:

  • UnivMed, France
  • IDIBAPS, Spain
  • University of Lille; INSERM, France
  • University of Foggia, Italy
  • Qualissima
  • Merck Serono
  • Roche
  • Eisai Ltd



Last Updated: Tuesday 26 April 2011


  • Acknowledgements

    The research leading to these results has received funding from the European Community's Seventh Framework Programme (FP7/2007-2013) for the Innovative Medicine Initiative under Grant Agreement No 115009.
  • Innovative Medicines Initiative
  • European Union
  • European Federation of Pharmaceutical Industries and Associations